{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Thalassemia Survey
  1. What is the average dose of Deferasirox dispersible tablet (DT) , considering all transfusion dependent thalassemia patients in your practice*
    2. Ans mg
  2. What are the 2 most common adverse effects you see in your patients undergoing iron chelation treatment with deferasirox DT?*
    3. A
    B
  3. Approximately what percentage of your patients do adhere to the prescribed dose and schedule of Deferasirox DT in your practice*
    4. Ans %
  4. Deferasirox DT requires oral administration on a daily basis. As a clinician do you agree adherence to recommended schedule is important for improved survival? (please tick) *

  5. Deferasirox DT contains lactose Monohydrate & sodium lauryl sulphate. These are found to be responsible for GI adverse events like Abdominal pain, nausea, vomiting, diarrhea etc. Do your patients complain of GI toxicities while on therapy with Deferasirox DT? (Please tick) *

  6. If “YES”, what percentage of your patients do complain of GI intolerance
    7. Ans %
  7. In such patients is there a problem with adherence to recommended dose / schedule? (Please tick) *

  8. How do you manage your patients with GI intolerance due to Deferasirox DT? (Please tick) *

  9. Deferasirox film-coated tablet (FCT) formulation, has improved gastrointestinal (GI) tolerability compared with deferasirox DT, offers a better option for improved compliance to long term therapy. In your patients with GI adverse events, would you like to use Deferasirox FCT? (Please tick) *

  10. If the cost difference is less, would you consider starting Deferasirox FCT from the beginning of iron chelation therapy? (Please tick one) *